After ASHG, Analysts Say Future is 'Murky' for Expression Arrays, 'Secure' for Genotyping Chips

Writing in separate research notes, Leerink Swann's Dan Leonard and Goldman Sachs' Isaac Ro both cited the recent availability of new sample-preparation kits and higher-throughput instruments as evidence of the gene expression market "tipping in favor" of sequencing over microarrays.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.